Introduction {#s1}
============

Colorectal cancer (CRC) is the third most common type of cancer in the western world and is responsible for approximately 50,000 deaths per year [@pone.0060607-Jemal1]. Family-based studies have suggested that the disease has a significant genetic component, with a large twin study conducted in Scandinavian countries suggesting that as many as 35% of colorectal cancers may be due to inherited susceptibility [@pone.0060607-Lichtenstein1]. However, the recognized Mendelian predisposition syndromes, such as hereditary nonpolyposis colorectal cancer and adenomatus polyposis coli, account for less than 5% of the overall incidence of colorectal cancer [@pone.0060607-Calvert1]. Therefore, common, low-penetrance polymorphisms may confer a substantial part of the genetic risk, but given that the estimated effect of each polymorphism is expected to be small, large studies are necessary to reduce the size-related uncertainty of effects and provide robust evidence of association.

Specific components of the western diet including meat consumption (particularly red and/or well-done meat) and dietary fat (particularly polyunsaturated fatty acids) have been proposed as risk factors which influence susceptibility to colorectal cancer [@pone.0060607-Bartsch1]--[@pone.0060607-deVerdier1]. It has been suggested that this may be due to carcinogenic polycyclic aromatic hydrocarbons (PAH) and heterocyclic amines (HCA) produced when meat is cooked at high temperatures. Data from both in vitro and in vivo studies suggest that exposure to PAH significantly increase colorectal cancer risk [@pone.0060607-Nagao1], [@pone.0060607-Sugimura1]. Cytochrome P450 2C9 (CYP2C9) is a key P450 enzyme which plays an important role in the metabolism and bioactivation of many dietary and environmental mutagens [@pone.0060607-Schwarz1]. A variety of studies have demonstrated that the metabolism of PAH and other procarcinogens through CYP2C9 may well lead to the activation of the carcinogenic compounds [@pone.0060607-Gooderham1], [@pone.0060607-Oda1]. CYP2C9 enzyme activity in man is modulated by genetic polymorphisms. The variant alleles *CYP2C9*\*2 (R144C) and \*3 (I359L) produce slow-metabolizing enzymes compared with wild-type *CYP2C9*\*1 [@pone.0060607-SullivanKlose1], [@pone.0060607-Gill1]. Hence, *CYP2C9* gene may be a good candidate for genetics studies on CRC.

Over the past few years, considerable efforts have been devoted to exploring the relationships between the *CYP2C9* polymorphisms and CRC risk among various populations. But the results are not always consistent. There are several possible explanations for this discordance, such as small sample size, ethnic background, uncorrected multiple hypothesis testing, and publication bias. Meta-analysis is a statistical procedure for combining the results of several studies to produce a single estimate of the major effect with enhanced precision. It has become important in cancer genetics because of rapid increases in the number and size of datasets. The aim of the present study is to perform a comprehensive meta-analysis to evaluate the association between the *CYP2C9* \*2 and \*3 polymorphism and CRC.

Materials and Methods {#s2}
=====================

Literature search strategy {#s2a}
--------------------------

We searched the PubMed, Embase, and ISI Web of Science for all articles on the association between *CYP2C9* polymorphisms and CRC risk published before the end of May 2012. The following keywords were used: "colorectal" or "colo\*," "cancer" or "tumor" or "carcinoma," and "*CYP2C9*" or "cytochrome P450 2C9". Additional studies were identified by a hand search of references of original studies and review articles on the association between the *CYP2C9* polymorphism and CRC. No language restrictions were applied.

Inclusion and exclusion criteria {#s2b}
--------------------------------

We reviewed abstracts of all citations and retrieved studies. The following criteria were used to include published studies: (i) identification of colorectal cancer cases was confirmed histologically or pathologically, (ii) case--control or cohort studies to evaluate the association between *CYP2C9* \*2 or \*3 polymorphism and CRC risk and (iii) genotype distribution information in cases and controls or odds ratio (OR) with its 95% confidence interval (CI) and P-value. Major reasons for exclusion of studies were (i) review, or editorial, or comment; (ii) duplicated studies; (iii) no sufficient data were reported.

Data abstraction {#s2c}
----------------

Two investigators extracted information from all eligible publications independently according to the inclusion criteria listed above. Disagreements were resolved by discussion with co-authors. For each included study, the following information was extracted from each report according to a fixed protocol: first author\'s surname, publication year, definition and numbers of cases and controls, diagnostic criterion, frequency of genotypes, source of controls, gender, age, Hardy--Weinberg equilibrium (HWE) status, ethnicity and genotyping method.

Statistical methods {#s2d}
-------------------

We first assessed HWE in the controls for each study using goodness-of-fit test (chi-square or Fisher\'s exact test) and a P\<0.05 was considered as significant disequilibrium. The strength of the association between CRC and the *CYP2C9* \*2 and \*3 polymorphism was estimated using ORs, with the corresponding 95% CIs. For the \*2 polymorphism, we first estimated the risks of the \*2 heterozygous and \*2 homozygote genotypes on CRC, compared with the wild-type \*1 homozygote. The risk of \*2 carrier versus \*1 on cancers was then evaluated in dominant model. The same evaluation was carried out for the \*3 polymorphism.

Both the Cochran\'s Q statistic [@pone.0060607-Cochran1] to test for heterogeneity and the I^2^ statistic to quantify the proportion of the total variation due to heterogeneity [@pone.0060607-Higgins1] were calculated. Random-effects and fixed-effect summary measures were calculated as inverse-variance-weighted average of the log odds ratio. The results of random-effects summary were reported in the text because it takes into account the variation between studies. The significance of the overall OR was determined by the Z-test. Subsidiary analyses included subgroup analyses or random-effects meta-regression with restricted maximum likelihood [@pone.0060607-Thompson1]. Ethnicity (Caucasian vs Asian), HWE status among control (yes or no), diagnostic criterion (ICD-9 vs. others), sample size (≥500 cases or \<500 cases) and sex were pre-specified as characteristics for the assessment of heterogeneity. Ethnicity, sample size, HWE status, and sex distribution in cases and controls were analyzed as covariates in meta-regression.

In order to assess the stability of the results, one-way sensitivity analyses were performed by removing each individual study in turn from the total and re-analyzing the remainder. Egger\'s regression test and funnel-plot analysis were used to assess publication bias [@pone.0060607-Begg1], [@pone.0060607-Egger1]. Analyses were performed using the STATA software version 10.0 (Stata Corporation, College Station, TX, USA). All P values are two-sided at the P = 0.05 level.

Results {#s3}
=======

Characteristics of studies {#s3a}
--------------------------

There were 63 papers relevant to the searching terms. The study selection process is shown in [Figure S1](#pone.0060607.s001){ref-type="supplementary-material"}. A total of 13 studies examined the association between the *CYP2C9* polymorphism and CRC were included in the current meta-analysis [@pone.0060607-Sainz1]--[@pone.0060607-Martnez1]. Among them, 12 studies were identified for the *CYP2C9* \*2 polymorphism, including a total of 9154 cases and 10900 controls, and for the \*3 polymorphism 12 studies were identified covering a total of 7701 cases and 9287 controls. Characteristics of studies included in the current meta-analysis are presented in [Table 1](#pone-0060607-t001){ref-type="table"}.

10.1371/journal.pone.0060607.t001

###### Characteristics of the studies included in the meta-analysis.

![](pone.0060607.t001){#pone-0060607-t001-1}

  Reference                                 Year   Ethnicity           Case              Control     No. of case   No. of control   Sex in case/control (male%)   MAF in controls   Genotyping method  
  ---------------------------------------- ------ ----------- ----------------------- ------------- ------------- ---------------- ----------------------------- ----------------- ------------------- --------------
  Sainz [@pone.0060607-Sainz1]              2011    German            ICD-10             Healthy        1768            1783                 58.6/59.8                 0.12               0.06          KASPar assay
  Cleary [@pone.0060607-Cleary1]            2010   Canadian            ICD-9             Healthy        1165            1292                 41.0/56.0                 0.14               0.07             Taqman
  Northwood [@pone.0060607-Northwood1]      2010    British    Colonoscopy confirmed     Healthy         308            296                  71.3/58.8                 0.11               0.07             Taqman
  Buyukdogan [@pone.0060607-Buyukdogan1]    2009    Turkish        CRC patients          Healthy         77              78                  52.0/53.0                 0.11               0.05             RT-PCR
  Cotterchio [@pone.0060607-Cotterchio1]    2008   Canadian            ICD-9             Healthy         834            1249                   NA/NA                   0.14               0.07             Taqman
  Liao [@pone.0060607-Liao1]                2007    Chinese        CRC patients          Healthy         284            483                  54.5/53.6                   /                0.03           Sequencing
  Küry [@pone.0060607-Kry1]                 2007    French         CRC patients          Healthy        1013            1118                 62.0/54.0                 0.14                 /              Taqman
  Samowitz [@pone.0060607-Samowitz1]        2006   American            ICD-9             Healthy        2295            2903                 57.1/54.6                 0.18               0.02          RFLP, TaqMan
  McGreavey [@pone.0060607-McGreavey1]      2005    British            ICD-9             Healthy         490            592                  61.0/54.0                 0.14               0.07             Taqman
  Tranah [@pone.0060607-Tranah1]            2005   American        CRC patients          Healthy         416            825                     0/0                    0.17               0.08             Taqman
  Landi [@pone.0060607-Landi1]              2005    Spanish        CRC patients        Cancer free       364            324                    NA/NA                   0.13               0.08           Sequencing
  Chan [@pone.0060607-Chan1]                2004   American     Histology confirmed      Healthy         339            350                     0/0                    0.09               0.08             Taqman
  Martínez [@pone.0060607-Martnez1]         2001    Spanish     Histology confirmed      Healthy         110            123                  53.0/53.0                 0.19               0.20              RFLP

ICD: International Classification of Diseases, HB: hospital-based, PB: population-based, MAF: minor allele frequency, NA: not available.

CYP2C\*2 and CRC risk {#s3b}
---------------------

The pooled estimate for CRC risk of *CYP2C9* \*2 polymorphism is shown in [Figure? 1](#pone-0060607-g001){ref-type="fig"}. The comparison between CRC cases and controls was investigated in 15 data sets. Overall, there was no significant heterogeneity among the studies concerning CRC risk of *CYP2C9* \*2 polymorphism (P\>0.05). The combined OR from the fixed-effects model was not significant with OR of 0.94 (95% CI: 0.87--1.03, P = 0.18) for the variant carriers. Similarly, no significant associations were found for heterozygous (OR = 0.92, 95% CI: 0.85--1.00, P = 0.06) and homozygous (OR = 1.19, 95% CI: 0.98--1.45, P = 0.07) when compared with wild genotype. Subgroup analysis for CRC risk of *CYP2C9* \*2 was also performed to explore the sources of heterogeneity. In the subgroup analyses by ethnicity, sample size, HWE status, diagnostic criteria and sex, no significant results were found in almost all genetic models ([Table 2](#pone-0060607-t002){ref-type="table"}).

![Forest plot (random effects model) of colorectal cancer risk associated with the CYP2C9 \*2 carrier of the R144C polymorphism.](pone.0060607.g001){#pone-0060607-g001}
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###### Meta-analysis of the *CYP2C9* \*2 polymorphism on colorectal cancer susceptibility.

![](pone.0060607.t002){#pone-0060607-t002-2}

  Sub-group analysis      No. of data sets   No. of case/control     Heterozygous      Homozygous   Variant carrier                                                                                  
  ---------------------- ------------------ --------------------- ------------------- ------------ ----------------- ----- ------------------- ------ ------ ----- ------------------- ------ ------ -----
  Total                          15              9154/10900        0.92 (0.85--1.00)      0.06           0.12         31%   1.19 (0.98--1.45)   0.07   0.50   0%    0.94 (0.87--1.03)   0.18   0.09   35%
  Ethnicity                                                                                                                                                                                          
  Caucasian                      14              9077/10822        0.92 (0.85--1.01)      0.07           0.09         35%   1.20 (0.99--1.46)   0.06   0.46   0%    0.95 (0.87--1.03)   0.21   0.07   39%
  Asian                          1                  77/78          0.72 (0.28--1.82)      0.48            NA          NA    0.64 (0.10--3.94)   0.63    NA    NA    0.70 (0.30--1.64)   0.41    NA    NA
  Sample size                                                                                                                                                                                        
  \<500                          8                2093/2566        0.93 (0.76--1.14)      0.50           0.06         48%   1.40 (0.86--2.29)   0.18   0.18   31%   0.97 (0.78--1.20)   0.77   0.03   55%
  ≥500                           7                7061/8334        0.92 (0.85--0.99)      0.03           0.35         10%   1.13 (0.91--1.42)   0.27   0.88   0%    0.93 (0.87--1.00)   0.05   0.48   0%
  HWE status                                                                                                                                                                                         
  Yes                            14              9077/10822        0.92 (0.85--1.01)      0.07           0.09         35%   1.20 (0.99--1.46)   0.06   0.46   0%    0.95 (0.87--1.03)   0.21   0.07   39%
  No                             1                  77/78          0.72 (0.28--1.82)      0.48            NA          NA    0.64 (0.10--3.94)   0.63    NA    NA    0.70 (0.30--1.64)   0.41    NA    NA
  Diagnostic criterion                                                                                                                                                                               
  ICD criterion                  7                6538/7808        0.90 (0.83--0.98)      0.01           0.38         6%    1.11 (0.88--1.40)   0.37   0.92   0%    0.92 (0.85--0.99)   0.03   0.54   0%
  Other criterion                8                2616/3092        0.95 (0.79--1.15)      0.62           0.07         47%   1.44 (0.90--2.29)   0.13   0.19   30%   0.99 (0.81--1.20)   0.92   0.03   54%
  Sex                                                                                                                                                                                                
  Male                           2                1273/1455        0.79 (0.52--1.18)      0.25           0.06         71%   1.27 (0.77--2.11)   0.35   0.60   0%    0.83 (0.59--1.18)   0.31   0.09   66%
  Female                         3                1238/1492        1.11 (0.85--1.44)      0.46           0.17         44%   0.92 (0.34--2.45)   0.86   0.10   57%   1.09 (0.79--1.51)   0.60   0.06   64%

NA: not available.

Although the formal test for heterogeneity was not significant, we conducted meta-regression as there were also grounds for considering the ethnicity, sample size, HWE status, and sex distribution among cases and controls as potential sources of heterogeneity. However, the meta-regression showed that none of these covariates significantly contributed to the heterogeneity among the individual study results (P\>0.05 for all).

CYP2C9 \*3 and CRC risk {#s3c}
-----------------------

Overall, the variant genotypes of the *CYP2C9* \*3 were not associated with CRC risk when compared with the wild-type \*1 homozygote (\*3 heterozygous: OR = 1.00, 95% CI = 0.86--1.17, P = 0.99; \*3 homozygous: OR = 0.87, 95% CI = 0.43--1.74, P = 0.69). Similarly, no associations were observed in the dominant genetic model (OR = 1.00, 95% CI = 0.86--1.16, P = 0.99; [Figure 2](#pone-0060607-g002){ref-type="fig"}). On the basis of the potential underestimation of the true effect of the polymorphism on the CRC risk, we stratified these studies according to ethnicity, sample size, HWE status, diagnostic criteria and sex. In stratified analyses, the variant genotypes had no significant relationship with CRC in all of the subgroups, compared with wild-type. Similar results were observed in the dominant genetic model ([Table 3](#pone-0060607-t003){ref-type="table"})

![Forest plot (random effects model) of colorectal cancer risk associated with the CYP2C9 \*3 carrier of the I359L polymorphism.](pone.0060607.g002){#pone-0060607-g002}
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###### Meta-analysis of the *CYP2C9* \*3 polymorphism on colorectal cancer susceptibility.

![](pone.0060607.t003){#pone-0060607-t003-3}

  Sub-group analysis      No. of data sets   No. of case/control     Heterozygous      Homozygous   Variant carrier                                                                                    
  ---------------------- ------------------ --------------------- ------------------- ------------ ----------------- ----- -------------------- ------ ------ ----- ------------------- ------ ------- -----
  Total                          15               7701/9287        1.00 (0.86--1.17)      0.99           0.007        54%   0.87 (0.43--1.74)    0.69   0.32   14%   1.00 (0.86--1.16)   0.99   0.008   53%
  Ethnicity                                                                                                                                                                                            
  Caucasian                      13               7343/8734        0.96 (0.85--1.08)      0.49           0.18         26%   0.87 (0.43--1.74)    0.69   0.32   14%   0.96 (0.85--1.07)   0.45   0.20    24%
  Asian                          2                 358/553         1.92 (0.87--4.25)      0.11           0.16         50%           NA            NA     NA    NA    1.92 (0.87--4.25)   0.11   0.16    50%
  Sample size                                                                                                                                                                                          
  \<500                          9                2314/2933        0.99 (0.74--1.33)      0.95           0.001        69%   1.44 (0.49--4.19)    0.51   0.56   0%    1.00 (0.75--1.33)   0.99   0.002   68%
  ≥500                           6                5387/6354        1.00 (0.88--1.13)      0.97           0.46         0%    0.65 (0.25--1.66)    0.37   0.23   27%   0.98 (0.87--1.11)   0.76   0.40    2%
  HWE status                                                                                                                                                                                           
  Yes                            13               7443/8786        1.05 (0.90--1.22)      0.52           0.02         49%   0.87 (0.43--1.74)    0.69   0.32   14%   1.05 (0.90--1.21)   0.54   0.02    49%
  No                             2                 258/521         0.65 (0.42--1.01)      0.05           0.25         25%           NA            NA     NA    NA    0.65 (0.42--1.01)   0.05   0.25    25%
  Diagnostic criterion                                                                                                                                                                                 
  ICD criterion                  7                5877/6946        1.01 (0.90--1.14)      0.85           0.53         0%    0.66 (0.31--1.38)    0.27   0.33   13%   0.99 (0.89--1.11)   0.91   0.48    0%
  Other criterion                8                1824/2341        0.97 (0.69--1.36)      0.85          0.0007        72%   3.32 (0.67--16.49)   0.14   0.92   0%    0.98 (0.70--1.38)   0.92   0.001   71%
  Sex                                                                                                                                                                                                  
  Male                           2                1257/1391        0.84 (0.67--1.06)      0.15           0.66         0%    0.67 (0.11--4.02)    0.66    NA    NA    0.84 (0.67--1.06)   0.14   0.65    0%
  Female                         3                1199/1437        1.14 (0.88--1.49)      0.32           0.27         24%   2.10 (0.52--8.43)    0.29   0.94   0%    1.15 (0.88--1.52)   0.30   0.25    29%

NA: not available.

In meta-regression analysis, sample size (p = 0.93), gender of cases (P = 0.34) and controls (P = 0.37), diagnostic criteria (P = 0.91) and the status of Hardy--Weinberg equilibrium (p = 0.05) did not significantly explained such heterogeneity. By contrast, ethnicity (P = 0.001) were significantly correlated with the magnitude of the genetic effect.

Sensitivity analyses and Publication bias {#s3d}
-----------------------------------------

A single study involved in the meta-analysis was deleted each time to reflect the influence of the individual dataset to the pooled ORs, and the corresponding pooled ORs were not qualitatively altered, suggesting that the results of this meta-analysis are stable ([Figure S2](#pone.0060607.s002){ref-type="supplementary-material"} and [S3](#pone.0060607.s003){ref-type="supplementary-material"}). In addition, when excluding the studies that were not in HWE, the results were persistent and robust ([Table 2](#pone-0060607-t002){ref-type="table"} and [3](#pone-0060607-t003){ref-type="table"}). The shape of the funnel plot did not indicate any evidence of obvious asymmetry ([Figure S4](#pone.0060607.s004){ref-type="supplementary-material"} and [S5](#pone.0060607.s005){ref-type="supplementary-material"}), thus suggesting no publication bias among the studies included. The statistical results still did not show preferential publication of positive findings in smaller studies (Egger test, P = 0.96 for \*2 carrier; P = 0.95 for \*3 carrier).

Discussion {#s4}
==========

A number of factors predict CRC; however, detailed mechanisms of CRC remain a matter of speculation. However, accumulative evidences have suggested an important role for genetics in determining risk for CRC [@pone.0060607-Lichtenstein1]. Association studies are appropriate for searching susceptibility genes involved in CRC [@pone.0060607-Risch1]. CYP2C9 is a key P450 enzyme implicated in the metabolism of exogenous and endogenous substrates. A variety of studies have demonstrated that the metabolism of polycyclic aromatic hydrocarbons and other procarcinogens through CYP2C9 may well lead to the activation of the carcinogenic compounds [@pone.0060607-Cleary1], [@pone.0060607-Tranah1]. *CYP2C9* is a polymorphic gene in the human population; the genetic variations have been studied with respect to a variety of cancer types. In recent years, a number of molecular epidemiologic studies have been conducted to evaluate the role of \*2 and \*3 polymorphisms in the *CYP2C9* gene on CRC risk; however, the results remain conflicting rather than conclusive. As a powerful statistical method, meta-analysis can provide a quantitative approach for pooling the results of different research on the same topic, and thus a quantitative assessment of association between *CYP2C9* polymorphism and CRC risk was of great value. The present meta-analysis, including 9463 cases and 11416 controls from 13 case--control studies, explored the association between the \*2 and \*3 polymorphism of *CYP2C9* gene and CRC risk. To the best of our knowledge, this is the first comprehensive meta-analysis concerning the relationship between *CYP2C9* polymorphism and CRC susceptibility. Overall, we did not find any significant association between *CYP2C9* \*2, \*3 polymorphism and CRC susceptibility. In the stratified analysis by ethnicity, sample size, HWE status, diagnostic criteria and sex, significant associations were still not observed in all genetic models. *CYP2C9* genotype was not found to be a determinant of colorectal cancer susceptibility according to the results of present meta-analysis.

Although CYP2C9 is active in the metabolism of several commonly prescribed drugs, including warfarin, phenytoin and non-steroidal anti-inflammatory drugs (NSAIDs) [@pone.0060607-Lee1], its role in xenobiotic and carcinogen metabolism is less well defined, although it has been shown to metabolize the carcinogen benzo\[a\]pyrene (B\[a\]P) to the highly mutagenic metabolite B\[a\]P-7,8diol-9,10-epoxide [@pone.0060607-Shou1]. *CYP2C9*\*3 encodes a protein with approximately 5--30% of the activity of the common reference allele [@pone.0060607-Takahashi1], and it could therefore be hypothesized that *CYP2C9*\*3 allele carriers have reduced carcinogen activating ability and thus reduced disease risk. However, the increased CRC risk associated with *CYP2C9*\*2 genotype in earlier studies suggests that the enzyme may play a more important role in detoxification of carcinogens.

Epidemiological data indicated the use of NSAID is inversely associated with the risk of developing colorectal cancer [@pone.0060607-Baron1]. Metabolism of NSAIDs involves oxidation by CYP enzymes and/or conjugation, particularly glucuronidation by phase II enzymes. The major enzymes involved are CYP2C9 and UGT1A6, both enzymes have variant forms [@pone.0060607-McGreavey1]. The modulation of chemoprevention of NSAIDs on CRC risk by the genotype of *CYP2C9* and *UGT1A6* has been reported among Caucasian population [@pone.0060607-McGreavey1], [@pone.0060607-Haining1]. Recently, the interaction between *UGT1A6* and *CYP2C9*, aspirin or ibuprofen use, and CRC risk were determined in 2295 CRC cases and 2903 controls. Their data showed the enhanced effect of slower-metabolizing *CYP2C9* variants on the chemopreventive activity of ibuprofen against CRC, and CYP variants were more effective in individuals with wild-type rather than variant *UGT1A6* [@pone.0060607-Samowitz1]. Therefore, the contribution of gene -- gene interaction as well as gene -- medication interaction should be considered in future study in elucidating the contribution of *CYP2C9* polymorphism to CRC etiology.

Although there is no association between *CYP2C9* \*2, \*3 polymorphism and the risk of CRC, the associations between *CYP2C9* polymorphism and CRC risk might be modified when exposed to some factors such as tobacco smoking [@pone.0060607-Chan1]. Chan et al [@pone.0060607-Chan1] reported that *CYP2C9* genotypes modified the CRC risk associated with smoking status. Women with variant genotypes who smoked \>20 pack-years had a 2.5-fold greater odds of adenoma compared with women with wild-type genotypes who smoked ≤20 pack-years. Because of limited data in primary studies, we could not quantitatively analyze the modification effects of smoking on the relationships between *CYP2C9* polymorphisms and CRC risk.

Limitations also inevitably existed in this meta-analysis. Firstly, most studies were conducted in Caucasian population. Therefore, it could be under powered to detected the interaction among Asian population in subgroup analysis. Hence, further studies including a wider spectrum of subjects should be carried to investigate the role of these variants in different populations. Secondly, our results were based on unadjusted estimates since we did not have original data. Therefore, we were not able to take into account other factors like obesity, inflammation, aspirin/NSAID use, vitamin D and vitamin E intake, which may modify the risk estimates, as reported in previous publications. Thus, assessment of the association between *CYP2C9* polymorphism and these covariates and CRC is needed in order to determine clearly the impact of *CYP2C9* polymorphism on the etiology of CRC. Thirdly, meta-analysis is a type of retrospective study, and the recall and selection bias might exist. In spite of these, our meta-analysis also had some advantages. First, substantial numbers of cases and controls were pooled from different studies, which significantly increased the statistical power of the analysis. Second, no publication bias was detected; indicating that the whole pooled result may be unbiased.

In conclusion, this meta-analysis evaluates the relation-ship between genetic polymorphism and CRC risk and reveals that *CYP2C9* \*2 and \*3 polymorphism is not associated with altered susceptibility to CRC. As studies among other populations are currently limited, further studies including a wider spectrum of subjects should be carried to investigate the role of these variant in these populations, which should lead to better, comprehensive understanding of the association between the *CYP2C9* polymorphism and CRC.

This meta-analysis is guided by the PRISMA statement ([Checklist S1](#pone.0060607.s006){ref-type="supplementary-material"}).
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